Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 5/20 | 0.49 |
| ▸ | GPR3 | P46089 | 4/20 | 0.46 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL365669 | 0.86 | GCGR (0.52) | GCGRMEN1HTTRAB9AKMT2A | |
| SCHEMBL7687597 | 0.86 | ALDH1A1 (0.47) | APPMAPTGCGRP2RX1MEN1 | |
| SCHEMBL20639207 | 0.85 | GPR3 (0.41) | APPGPR3WDR5MAPTGCGR | |
| SCHEMBL24445841 | 0.83 | GPR3 (0.48) | GPR3WDR5MAPTEPHX2KIF11 | |
| SCHEMBL7691093 | 0.82 | APP (0.52) | APPKMT2AKCNH2TMEM97SIGMAR1 | |
| SCHEMBL20638763 | 0.82 | GCGR (0.43) | APPGPR3WDR5GCGRL3MBTL1 | |
| SCHEMBL8940653 | 0.82 | ALDH1A1 (0.49) | APPMAPTL3MBTL1MEN1HTT | |
| SCHEMBL7691095 | 0.82 | APP (0.43) | APPGPR3WDR5GCGRL3MBTL1 | |
| SCHEMBL8940652 | 0.82 | L3MBTL1 (0.47) | APPMAPTL3MBTL1MEN1KMT2A | |
| SCHEMBL24445818 | 0.82 | WDR5 (0.43) | APPGPR3WDR5GCGREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1565430-B1 | BIGUANIDE DERIVATIVES | JACOBUS PHARMA CO INC (US) | 2010-02-17 | — | — | EP | disclosed |
| US-7563792-B2 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080176852-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7256218-B2 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1565430-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL CO. INC. (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040116428-A1 | Biguanide and dihydrotriazine derivatives | JACOBUS PHARMACEUTICAL COMPANY, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004048320-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | JACOBUS PHARMACEUTICAL COMPANY, INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| EP-0778267-A1 | SULFONAMIDE DERIVATIVES AND INSECTICIDE, MITICIDE AND NEMATICIDE CONTAINING THE SAME | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | APP 4262/4885GPR3 80/4885WDR5 2342/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | APP 4602/4885GPR3 563/4885WDR5 1784/4885 |
| US-20080176852-A1 | BIGUANIDE AND DIHYDROTRIAZINE DERIVATIVES | QDPR, DHODH, GLMN | APP 3364/4885GPR3 2395/4885WDR5 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.